A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic (PK) of Single-dose Administration of Semaglutide Nasal Spray (WL1006) in Adult Overweight or Obese Participants

Inclusion Criteria: 1. Male or female participants aged ≥18 years and ≤ 65 years. 2. Body Mass Index (BMI) at screening between 27.0 and 35.0 kg/m² (inclusive). 3. Weight change of no more than ±5% during the 3 months prior to screening with diet and exercise alone (self-reported). 4. Participants (including males) must have no plans for conception during the study and within 3 months after the last administration, and must agree to use effective contraceptive methods and refrain from donating sperm or eggs during this period. 5. Negative anti-HIV antibody test result at screening. 6. Partici…